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Pain is still a major public health problem, with a high prev-
alence of both acute and chronic conditions. The inclusion 
of genomic (and other omics) technologies represents a 
new approach in pain research. However, new research 
and diagnostic tools in the field of health care always re-
quire a detailed study of ethical aspects and implications. 
In particular, pain research represents an area with many 
challenges when it comes to ethical aspects. Using place-
bo treatment, an agent biologically inert in respect to pain 
condition but potentially helpful for the patient, represents 
a classic paradigmatic type of ethical concerns in this area 
(1,2). Placebo treatment is based on the concept of decep-
tion. It undermines honest relationship and trust between 
doctor and patient, which is extremely important for a suc-
cessful treatment (1). Still, application of placebo in terms 
of analgesia will cause a positive response in 35% of pa-
tients (3). It is important to highlight that response to pla-
cebo does not mean that the patient is faking the pain and, 
therefore, it would be unethical to withhold the specific 
treatment. Functional magnetic resonance imaging of the 
brain showed that placebo analgesia produces activation 
of relevant brain areas (4). On the other hand, intentionally 
giving placebo treatment for a condition that can be ad-
equately treated would be against the right of patients to 
receive the best possible care.
Another controversial subject are patients unable to “cor-
rectly” express pain or to give consent. In animal research, 
important improvements are made in order to avoid suffer-
ing and pain of the involved animals (5). But what happens 
when the main issue of research is pain? Animal research is 
intended to be limited to those studies where the animal 
model is the only possibility. A controversial editorial com-
ment in Nature Neuroscience, with the provocative title 
“Italian biomedical research under fire,” pointed out the risks 
of excessive restrictions in animal research (6). Although 
there is an overall agreement to avoid “avoidable” pain, the 
question remains what is “avoidable.” A particular issue is fe-
tal, neonatal, and infant pain. In 1985, the infant Jeffrey Law-
son underwent open heart surgery awake and conscious 
throughout the entire procedure. The opinion of the anes-
thesiologist was that it had never been demonstrated that 
premature babies felt pain (7). In contrast, recently a study 
protocol including the use of placebo control to study neo-
natal pain in an intensive care unit has not been approved 
by the institutional review board (8). However, fetal sur-
geries continue to be performed with little (or no) regard 
about pain. Practical problems such as correct monitoring 
and physiological issues (immaturity of the central nervous 
system) can be difficult to address even in a standard ap-
proach. Pain research in cognitively impaired people is of 
particular interest because the prevalence of both condi-
tions increases with age. There has been considerable evi-
dence on inadequate assessment and treatment of pain in 
this vulnerable population. It seems that unfortunately re-
search that supports best practices for assessing and treat-
ing pain in cognitively impaired patients is limited by meth-
odological obstacles (9). In the current practice of clinical 
research, this population is excluded from studies. The de-
velopment of new monitoring tools for animal and human 
pain could be an innovative path to resolve these problems. 
The desired result would be to maintain the minimum in-
tensity of pain required to achieve the goals of the study 
and to hold this level of intensity during its entire course.
Another important point in pain research is the lack of 
knowledge about pain treatment by the general popula-
tion, and in particular by health care personnel (10). Physi-
cians and nurses involved in pain treatment showed lack 
of preparation regarding pain (11) and patients had mis-
conceptions about pain treatment. Famous examples are 
that the use of opioids always produces addiction and that 
“pain is part of the cure.” Some countries, like Italy, modi-
fied the law to include mandatory pain monitoring in the 
clinical records (12). At the moment, several medical asso-
ciations are studying the inclusion of pain assessment and 
treatment skills in the resident study programs.
Inclusion of genomic (and other omics) technologies in 
pain research represents a delicate topic and it raises 
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several questions and concerns. Genomic (and other om-
ics) technologies in the last two decades have produced 
not only a deep change in biomedical research, but also 
generated a change in the agenda of institutional review 
boards and research ethics. The potential to discover large 
amounts of possibly important incidental information dur-
ing the genomic analysis has been identified as one of the 
greatest challenges to genomic medicine (13). Debates 
should be focused on the physicians’ obligations arising 
from this type of the research, protection of the included in-
dividuals, and communication of such research to patients 
and the community (14). Omics analyses in humans raise 
complex ethical issues, which often significantly impact 
the pace of research programs. By working collaboratively, 
researchers intend to answer questions never addressed 
before, but at the same time different team members may 
have varied ethical perceptions due to differences in disci-
plines as well as legal traditions and cultures. Furthermore, 
recent studies have demonstrated how “easy” it is to de-
duce individual identity from diverse public data sets (Ge-
nomes Project Consortium Nature 2012) (15). The authors 
were able to establish the identity of close to 50 of the Cen-
ter for Study of Human Polymorphisms participants (both 
women and men). It is important to note that the authors 
did not reveal the names of the participants (or violated 
any known policies), but merely demonstrated their abil-
ity to identify them through the analysis of publicly avail-
able information. These findings alert us about how easy 
information is available in the era of information networks. 
Particular attention should be paid to preserve the privacy 
right in this new global village (16).
In conclusion, innovative tools in pain research could in-
troduce new answers to old questions. However, there are 
numerous ethical issues to consider. Ethical pain research 
should not only guarantee the right of patients to the cor-
rect treatment, but also it should assure the inclusion of 
excluded categories of patients (fetal, pediatric, and cog-
nitively impaired patients) with particular solutions for spe-
cific queries. The use of innovative models and monitor-
ing would be useful in this setting. Omics research adds 
an additional variable to the equation. It provides impor-
tant benefits to research, but increases the vulnerability of 
those affected when patients’ privacy is concerned.
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